A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

David B. Page; Isaac K Kim; Brie Chun; William L Redmond; Maritza Martel; Motomi Mori; Dottie Wadell; Nicole Moxon; Staci L. Mellinger; Walter John Urba; Ayca Gucalp; Tiffany A. Traina

doi:10.1200/JCO.2019.37.15_SUPPL.TPS1106

A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

David B. Page
, Isaac K Kim
, Brie Chun
, William L Redmond
, Maritza Martel
, Motomi Mori
, Dottie Wadell
, Nicole Moxon
, Staci L. Mellinger
, Walter John Urba
, Ayca Gucalp
, Tiffany A. Traina

Providence

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1200/JCO.2019.37.15_SUPPL.TPS1106
State	Published - May 20 2019

Disciplines

Oncology
Pathology
Medicine and Health Sciences

Access to Document

10.1200/JCO.2019.37.15_SUPPL.TPS1106License: Unspecified

Cite this

Page, D. B., Kim, I. K., Chun, B., Redmond, W. L., Martel, M., Mori, M., Wadell, D., Moxon, N., Mellinger, S. L., Urba, W. J., Gucalp, A., & Traina, T. A. (2019). A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC). Journal of Clinical Oncology, 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.TPS1106

@article{fe981cab43164df1ba9bdaa8440cf9e0,

title = "A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).",

author = "Page, \{David B.\} and Kim, \{Isaac K\} and Brie Chun and Redmond, \{William L\} and Maritza Martel and Motomi Mori and Dottie Wadell and Nicole Moxon and Mellinger, \{Staci L.\} and Urba, \{Walter John\} and Ayca Gucalp and Traina, \{Tiffany A.\}",

note = "TPS1106 Background: ICB (atezolizumab, anti-PD-L1) is known to improve survival when added to chemo, however only in PD-L1-positive, triple-negative MBC. ICB is less effective in hormone receptor positive (HR+) MBC, or when administered following palliative chemo. Novel approaches are required to broaden clinical benefit of ICB, particularly in PD-L1-negative, HR+, or chemo-experienced MBC.",

year = "2019",

month = may,

day = "20",

doi = "10.1200/JCO.2019.37.15\_SUPPL.TPS1106",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

}

Page, DB, Kim, IK, Chun, B, Redmond, WL, Martel, M, Mori, M, Wadell, D, Moxon, N, Mellinger, SL, Urba, WJ, Gucalp, A & Traina, TA 2019, 'A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).', Journal of Clinical Oncology, vol. 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.TPS1106

TY - JOUR

T1 - A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

AU - Page, David B.

AU - Kim, Isaac K

AU - Chun, Brie

AU - Redmond, William L

AU - Martel, Maritza

AU - Mori, Motomi

AU - Wadell, Dottie

AU - Moxon, Nicole

AU - Mellinger, Staci L.

AU - Urba, Walter John

AU - Gucalp, Ayca

AU - Traina, Tiffany A.

N1 - TPS1106 Background: ICB (atezolizumab, anti-PD-L1) is known to improve survival when added to chemo, however only in PD-L1-positive, triple-negative MBC. ICB is less effective in hormone receptor positive (HR+) MBC, or when administered following palliative chemo. Novel approaches are required to broaden clinical benefit of ICB, particularly in PD-L1-negative, HR+, or chemo-experienced MBC.

PY - 2019/5/20

Y1 - 2019/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS1106

U2 - 10.1200/JCO.2019.37.15_SUPPL.TPS1106

DO - 10.1200/JCO.2019.37.15_SUPPL.TPS1106

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

Disciplines

Access to Document

Other files and links

Cite this